Emopamil binding protein mutation in conradi-hünermann-happle syndrome representing plaque-type psoriasis
Kemal Ozyurt1, Asli Subasioglu2, Perihan Ozturk1
1Department of Dermatology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey.
Abstract:
Conradi-Hünermann-Happle syndrome (CDPX2, OMIM 302960) is an inherited X-linked dominant variant of chondrodysplasia punctata which primarily affects the skin, bones, and eyes. CDPX2 patients display skin defects, including ichthyotic lesions, follicular atrophoderma, cicatricial alopecia, and less frequently ichthyosiform erythroderma, cataracts, and skeletal abnormalities consisting of short stature, asymmetric shortening of the limbs, epiphyseal stippling, and craniofacial defects. CDPX2 results from mutations in emopamil binding protein (EBP) gene. The aim of our study is to identify EBP mutation in a unique case of Conradi-Hünermann-Happle syndrome with rare psoriasiform lesions.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pharmacogenomics: Identification of New Drug Targets
Cytoskeletal Linker Proteins - Plakins


